Oct
· CU01 Phase 2b Results in Diabetic Nephropathy Presented Orally at ICDM 2026
Sep
· MT-501 selected for an R&D project supported by the Ministry of SMEs and Startups
Aug
· Selected as a participating company in the Jeonbuk Next-Generation Veterinary Medicines Regulation-Free Special Zone for CP02
· CU72 selected for the Ministry of SMEs and Startups’ collaborative pharmaceutical–bio venture technology development program
Jun
· CU01 Phase 2b Results Presented at the ADA 2026
· MOU with the College of Pharmacy, Gyeongsang National University
· MOU with AIMBLE, an AI Drug Discovery Company
· MT-201 Selected for the Korea Drug Development Fund (KDDF) Program
May
· Preclinical Results of MT-103 Presented Orally at ARVO 2026
· Retinal Disease Bispecific Antibody MT-103 Licensed to Memento Medicines
Apr
· CU01 Phase 2b Clinical Trial CSR(Clinical Study Reports) received (Diabetic Nephropathy)
Feb
· Completed Merger with Active Pharmaceutical Ingredient (API) Company
Jan
· CU01 Phase 2b Topline Results Announced (Diabetic Nephropathy)